$AZN's ENHERTU continues to dominate the HER2-low cancer market with projected 9.4% CAGR through 2034. DATROWAY (Dato-DXd) Phase III progress and strong uptake in breast/gastric cancers reinforce AstraZeneca's leadership. With 63% of breast cancers classified HER2-low, pipeline depth positions AZN for sustained oncology growth.
prnewswire.com/news-release... Bullish